Guided Therapeutics (GTHP) Operating Leases (2019 - 2026)

Guided Therapeutics has disclosed Operating Leases across 8 years of filings, most recently posting $683000.0 for Q2 2026.

• In Q2 2026, Operating Leases rose 556.73% year-over-year to $683000.0; the TTM figure through Jun 2026 stood at $683000.0 (up 556.73% YoY), while the FY2025 annual figure was $696000.0, up 349.03% from the prior year.
• Operating Leases came in at $683000.0 for Q2 2026 at Guided Therapeutics, roughly flat from $685000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $696000.0 in Q4 2025 to a low of $76000.0 in Q3 2025.
• Average Operating Leases over 5 years is $301055.6, with a median of $256500.0 recorded in 2022.
• Year-over-year, Operating Leases tumbled 57.3% in 2025 and jumped 556.73% in 2026.
• Over 5 years, Operating Leases stood at $325000.0 in 2022, then retreated by 24.31% to $246000.0 in 2023, then tumbled by 36.99% to $155000.0 in 2024, then jumped by 349.03% to $696000.0 in 2025, then dropped by 1.87% to $683000.0 in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $683000.0 in Q2 2026, $685000.0 in Q1 2026, and $696000.0 in Q4 2025.